223 related articles for article (PubMed ID: 29650277)
1. Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment.
Del Re M; Crucitta S; Restante G; Rofi E; Arrigoni E; Biasco E; Sbrana A; Coppi E; Galli L; Bracarda S; Santini D; Danesi R
Crit Rev Oncol Hematol; 2018 May; 125():51-59. PubMed ID: 29650277
[TBL] [Abstract][Full Text] [Related]
2. T-LAK cell-originated protein kinase (TOPK) enhances androgen receptor splice variant (ARv7) and drives androgen-independent growth in prostate cancer.
Alhawas L; Amin KS; Salla B; Banerjee PP
Carcinogenesis; 2021 Apr; 42(3):423-435. PubMed ID: 33185682
[TBL] [Abstract][Full Text] [Related]
3. [Androgen receptor variants in prostate cancer].
Schreyer E; Barthélémy P; Cottard F; Ould Madi-Berthélémy P; Schaff-Wendling F; Kurtz JE; Céraline J
Med Sci (Paris); 2017; 33(8-9):758-764. PubMed ID: 28945566
[TBL] [Abstract][Full Text] [Related]
4. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ; Milowsky MI; Whang YE
Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
[TBL] [Abstract][Full Text] [Related]
6. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
Coutinho I; Day TK; Tilley WD; Selth LA
Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptors in early and castration resistant prostate cancer: friend or foe?
Pelekanou V; Notas G; Stathopoulos EN; Castanas E; Kampa M
Hormones (Athens); 2013; 12(2):224-35. PubMed ID: 23933691
[No Abstract] [Full Text] [Related]
9. Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries.
Obinata D; Takayama K; Inoue S; Takahashi S
Int J Urol; 2024 Jun; 31(6):590-597. PubMed ID: 38345202
[TBL] [Abstract][Full Text] [Related]
10. Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.
Buonerba C; Di Lorenzo G; Sonpavde G
Expert Rev Mol Diagn; 2016 Oct; 16(10):1113-1120. PubMed ID: 27665838
[TBL] [Abstract][Full Text] [Related]
11. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
[TBL] [Abstract][Full Text] [Related]
12. Emerging Variants of Castration-Resistant Prostate Cancer.
Vlachostergios PJ; Puca L; Beltran H
Curr Oncol Rep; 2017 May; 19(5):32. PubMed ID: 28361223
[TBL] [Abstract][Full Text] [Related]
13. Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy.
Kang YJ; Jang WS; Kwon JK; Yoon CY; Lee JY; Ham WS; Choi YD
BMC Cancer; 2017 Nov; 17(1):789. PubMed ID: 29169347
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer.
Seisen T; Rouprêt M; Gomez F; Malouf GG; Shariat SF; Peyronnet B; Spano JP; Cancel-Tassin G; Cussenot O
Cancer Treat Rev; 2016 Jul; 48():25-33. PubMed ID: 27327958
[TBL] [Abstract][Full Text] [Related]
15. Progress in the mechanism and drug development of castration-resistant prostate cancer.
Zuo M; Xu X; Li T; Ge R; Li Z
Future Med Chem; 2016 May; 8(7):765-88. PubMed ID: 27149562
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J
Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311
[TBL] [Abstract][Full Text] [Related]
17. Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.
Ferrari N; Granata I; Capaia M; Piccirillo M; Guarracino MR; Venè R; Brizzolara A; Petretto A; Inglese E; Morini M; Astigiano S; Amaro AA; Boccardo F; Balbi C; Barboro P
Cell Commun Signal; 2017 Dec; 15(1):51. PubMed ID: 29216878
[TBL] [Abstract][Full Text] [Related]
18. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
Gao S; Ye H; Gerrin S; Wang H; Sharma A; Chen S; Patnaik A; Sowalsky AG; Voznesensky O; Han W; Yu Z; Mostaghel EA; Nelson PS; Taplin ME; Balk SP; Cai C
Clin Cancer Res; 2016 Jul; 22(14):3672-82. PubMed ID: 26936914
[TBL] [Abstract][Full Text] [Related]
19. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
Liu L; Lou N; Li X; Xu G; Ruan H; Xiao W; Qiu B; Bao L; Yuan C; Huang X; Wang K; Cao Q; Chen K; Yang H; Zhang X
Oncol Rep; 2017 Jun; 37(6):3651-3659. PubMed ID: 28498452
[TBL] [Abstract][Full Text] [Related]
20. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
Murez T; Basset V; Audenet F; Lebret T; Branchereau J
Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
